Related to Foundation and Sanofi Sign Deal for Cancer Biomarkers and Companion Diagnostics

• Immune Response Markers for Cancer Vaccines Paint a Clearer Picture
  In trying to understand what constitutes an effective immune response, researchers find it’s all about T cells.
  
• Enzo Sues Roche, Gen-Probe, and Life Technologies in Patent Infringement Case
  Patent under dispute expires in 2023, and defendants plan on fighting the lawsuit.
  
• Myriad, Prometheus Continue to Defend Diagnostic Patents while Others Urge More Licensing
  Battle raged on at second USPTO hearing tasked with evaluating the impact of patents on the availability of confirmatory tests.
  
• Lawyers Offer Predictions for Myriad, Diagnostic Field Based on Supreme Court’s Decision Against Prometheus
  Advice focuses on ensuring transformative steps are included in claims.
  
• IOM Guidelines for Use of Omics Tests in Clinical Trials Add Rigor to Quality Assurance
  The report stresses the importance of independent researchers to verify initial biomarker discoveries.
  
• Autologous Immunotherapy Updates at ASCO Further Define Antitumor Immune Responses
  Biovest and Dendreon presented studies involving their respective vaccines in the neoadjuvant setting.
  
• With USPTO Report Near, Comments Reflect Confirmatory Diagnostic Testing Divide
  Dx makers would like to keep patent protection, but patient groups say it stifles broader access to genetic tests at lower cost.
  
• Patient Privacy or Scientific Advances: Do They Have to Be Mutually Exclusive?
  Presidential Commission weighs pros and cons of making sequencing data available to researchers and patients.
  
• Leveraging the Cancer Transcriptome for New Drug Targets
  New analytical tools are advancing research efforts.
  
• Harvard Professor Rides Genomics' Third Wave
  New Firm Aims to Advance Personalized Medicine through Precision Diagnostics
  
• Will Less SOX2 Lead to Brain Cancer Getting Cold Feet?
  PLK1 level is elevated in glioblastoma multiforme, and its inhibition restricts the growth of brain cancer cells.
  
• Are You Already Obsolete?
  To stay ahead in the ever-quickening world of research, scientists must be fast and cunning.
  
• Clinical Application of miRNAs Remains a Ways Off
  When and if its time comes, prognostic tests will likely be first.
  
• A SPA for PMTs
  Researchers propose a SPA strategy that can be successfully implemented to identify novel and specific inhibitors of PMTs.
  
• Blood Flow as Diagnostic Marker
  Jamming, or vaso-occlusion, could be used to distinguish sickle cell disease patients with poor outcomes from those with good outcomes.
  
• Leveraging Synthetic Lethality for Cancer Therapeutics
  Researchers investigate a class of therapeutics that could short-circuit cancer cells at the molecular level.
  
• Oncogene Addiction: Real or Not?
  Emerging documentation is starting to address that question and increase understanding of process.
  
• The Search for Depression Biomarkers
  The ability to predict drug responses more accurately is driving efforts.
  
• LAVAgel for Protein Diagnostics
  Researchers introduce a microfluidic, single-channel, multistage immunoblotting strategy toward scalable protein isoform analysis.
  
• End-Running Cancer Resistance to Targeted Therapies
  Overcoming resistance may require an assault on multiple fronts.